A Pilot Study Using Registry-Based External Controls for the Cyclosporine Arm of the BENEFIT Study
A Prospective Randomised, Controlled Trial Switching Sirolimus For Mycophenolate To Enhance Immunological Responses To Third Dose Covid-19 Vaccination In Kidney Transplant Recipients With Poor Baseline Humoral Immunity
Adherence, Outcomes and Adverse Effects in Pediatric Renal Transplant Patients After Early Steroid-Withdrawal and Low-Dose Calcineurin Inhibitor Maintenance Immunosuppression
Association Between De Novo Donor Specific Antibody and Tacrolimus Trough Levels in Long Term Follow Up Renal Transplantation
Conversion from Immediate to Extended-Release Tacrolimus (LCP-Tac) Six Months After Renal Transplantation Optimizes Safety and Efficacy
Conversion to Belatacept for Calcineurin Inhibitor Toxicities
Conversion to Everolimus-Based Immunosuppression Regimen with Calcineurin Inhibitor Reduction Ameliorates Histological Damage in Kidney Transplant Recipients with Calcineurin Inhibitor-Induced Nephrotoxicity
Covid-19 Vaccination Response In Tacrolimus Treated Kidney Transplant Recipients With And Without Mycophenolate Mofetil: Follow-up Of A Randomized Controlled Trial
De-Novo Belatacept Therapy is Associated with an Increased Risk of Invasive CMV Disease After Kidney Transplantation
De-Novo Belatacept Therapy is Associated with Higher Levels of BK Viremia and Lower Rates of BK Clearance in Kidney Transplantation Patients
- 1
- 2
- 3
- …
- 5
- Next Page »